MedTrace Logo

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

NCT03339778 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2017-11-13

No results posted yet for this study

Summary

Patients with primary immunodeficiency disorders (PID) on intravenous immunoglobulin (IVIG) treatment may experience adverse events (AEs). Patients who experience AEs on any 10% IVIG solution will be changed to octagam 5% for six infusions to evaluate the potential benefit for reduction of AEs on a lower concentration IVIG product.

Conditions

  • Primary Immunodeficiency

Sponsors & Collaborators

  • IMMUNOe Research Centers

    lead INDUSTRY

Principal Investigators

  • Isaac Melamed, MD · IMMUNOe Research Centers

Eligibility

Min Age
10 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-11-30
Completion
2017-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03339778 on ClinicalTrials.gov